AAV Factor VIII Vectors for Complete Packaging and High Expression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The limited DNA packaging capacity of adeno-associated virus (AAV) vectors, particularly for large therapeutic genes like Factor VIII, results in incomplete genome packaging and immune response issues, hindering effective gene therapy for hemophilia A.

Innovation Solution

Development of AAV vectors encoding functionally active Factor VIII proteins, optimized to be less than 7.0 kb in length, with enhanced promoter function, and incorporating specific transcription regulatory elements to ensure complete packaging and high expression activity, avoiding immune response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If the Factor VIII gene is used in AAV vectors, then therapeutic effect for hemophilia A is achieved, but the gene size exceeds the packaging capacity of AAV vectors

Engineering Contradiction:

Improvetherapeutic effectVSAvoidgene size

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The Factor VIII gene is divided into two separate expression cassettes: one encoding the heavy chain (A domain) and another encoding the light chain (C domain). These segmented genes are packaged into separate AAV vectors that co-infect target cells, where the individual chains self-assemble to form functional Factor VIII protein, thereby overcoming the packaging capacity limitation while maintaining therapeutic efficacy

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The central B domain is removed from the Factor VIII gene sequence, creating a truncated version that retains essential coagulation function. This extracted essential functional region reduces the overall gene size to fit within AAV packaging capacity while preserving the ability to treat hemophilia A through the remaining A and C domains

Inventive Principle:

Principle #2Taking out (Extraction)

2Quantity of substance

If two AAV vectors are used to encode heavy and light chains, then packaging capacity is respected, but vector complexity and delivery difficulty increase

Engineering Contradiction:

Improvepackaging capacity complianceVSAvoidvector system complexity

Core Design Contradiction:

Quantity of substanceVSDevice complexity

Solution Approach 1:

Two separate AAV vectors encoding the heavy and light chains are designed to co-infect the same target cells, where their genetic products spontaneously interact and assemble into functional Factor VIII. This merging approach allows compliance with packaging capacity constraints while maintaining a relatively simple dual-vector system that leverages natural protein assembly processes

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The cell's natural protein synthesis and assembly machinery serves as an intermediary that combines the products of two separate AAV vectors. Rather than requiring complex in vitro assembly or additional delivery mechanisms, the cellular environment facilitates the interaction between heavy and light chains to produce functional Factor VIII, simplifying the overall delivery system

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250332224A1Adeno-Associated Virus Factor VIII Vectors

Publication Date: 2025.10.30 BIOMARIN PHARMACEUTICAL INC

AI summary

The invention provides completely packaged adeno-associated virus (AAV) Factor VIII (FVIII) vectors. This invention also provides completely packaged AAV FVIII vectors with high expression activity.